Inmune Bio (INMB) Stock
Small biotech developing immune system therapies in trials. Here's the price, business snapshot, and what's worth knowing about Inmune Bio in October 2026.
INMUNE BIO INC (INMB) is a small‑cap, clinical‑stage biotechnology company focused on developing therapies that modulate innate immunity. With a market capitalisation of roughly $50 million, the company is likely pre‑revenue and dependent on clinical progress, partnerships and financing to advance its programmes. Key considerations for investors include high scientific and execution risk: clinical trial outcomes and regulatory decisions tend to be primary share‑price drivers, and positive data can materially affect valuation while setbacks may be swift. Cash runway and any licensing or collaboration agreements are important to monitor, as small biotechs frequently need further capital which can dilute existing holders. Liquidity may be limited and price moves can be volatile. This summary is for educational purposes only and not personalised financial advice; investors should assess the science, management, trial design and how a speculative biotech fits into a diversified, risk‑managed portfolio.
Inmune Bio (INMB) Stock Forecast
Analyst price target, next 12 months
$12.33
+539.0% vs today's $1.93
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Inmune Bio have a consensus 12-month target of $12.33, above the current price of $1.93.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying INMUNE BIO INC's stock, with a target price of $12.33.
Financial Health
Inmune Bio is managing its cash flow well, but its book value per share is relatively low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical‑stage focus
Progress depends on trial data and regulatory signals; positive results can change valuation quickly, though outcomes remain uncertain.
Catalysts to watch
Trial readouts, partnership announcements and financing updates can move the share price — monitor official filings and company releases.
Risk and liquidity
Small market cap often means higher volatility and limited liquidity; consider diversification and that this is educational, not personal advice.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
